[
  {
    "ts": null,
    "headline": "What the Options Market Tells Us About Moderna",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=e2993c1d1970760afdde05cb308b905b74b0433f51f8e012f13ff3c2d4ecfe5b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771948850,
      "headline": "What the Options Market Tells Us About Moderna",
      "id": 139209024,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=2048&height=1536",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=e2993c1d1970760afdde05cb308b905b74b0433f51f8e012f13ff3c2d4ecfe5b"
    }
  },
  {
    "ts": null,
    "headline": "Will the FDA yank mRNA vaccines?",
    "summary": "Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.",
    "url": "https://finnhub.io/api/news?id=072d2f416b83c4c2c44e6d24c6a827f179f1bde653f03c2d60d7670cebd3978d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771919572,
      "headline": "Will the FDA yank mRNA vaccines?",
      "id": 139194731,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.",
      "url": "https://finnhub.io/api/news?id=072d2f416b83c4c2c44e6d24c6a827f179f1bde653f03c2d60d7670cebd3978d"
    }
  }
]